Organon & Co.

Organon & Co.

OGNNYSE / NASDAQHealthcareMid cap

$13.89-$0.02 (-0.1%)

Last close · Data as of Nov 20, 2026

Market cap
$3.5B
P/E
18.8x
EV / EBITDA
9.0x
Revenue
$6.2B
Net margin
3.0%
ROCE
11.7%

+94.8% over the last year

Organon & Co. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.9%
3M
+1.1%
6M
+3.2%
1Y
+94.8%
5Y
-55.6%

52-week range

Day change -$0.02 (-0.1%) from $13.91 to $13.89 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in OGN, bought on each weekday since 2021.

News & filings

What Organon & Co. filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernDebt is more than ten times shareholders' equity.

Strengths (1)

  • Return on equity of 24.9% against a peer median of 7.0%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

Read moreShow less

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Sector
Healthcare
Shares outstanding
259.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.5B
P/E
18.8x
P/B
4.7x
EV / EBITDA
9.0x
EV / Sales
1.9x
P/S
0.6x
52-week high
$13.92
52-week low
$5.70

Profitability

Operating margin
19.7%
Net margin
3.0%
EBITDA margin
20.8%
ROE
24.9%
ROCE
11.7%
ROA
1.5%
Asset turnover
0.48

Growth

Revenue
$6.2B
Revenue growth, 1Y
-2.9%
Revenue CAGR, 3Y
0.2%
Net profit growth, 1Y
-78.4%
Free cash flow
$384.0M

Solvency

Current ratio
1.82
Debt / Equity
11.49
Debt / Assets
0.67
CFO / Net profit
3.74
Cash / Market cap
16.3%

Where the revenue went

Of every $100 of FY2025 revenue, $3 was left as net income.

Organon & Co. income statement flow, FY2025
Organon & Co. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.9B
RevenueGross profit$3.3B
Gross profitResearch and development$366.0M
Gross profitSelling, general and administrative$1.7B
Gross profitOperating income$1.2B
Operating incomePretax income$425.0M
Operating incomeInterest and other expense$801.0M
Pretax incomeTax and other$238.0M
Pretax incomeNet income$187.0M

Revenue and net profit

Revenue fell 2.9% in FY2025; net profit is the dashed line.

Organon & Co. revenue and net profit by fiscal year
Organon & Co. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$6.2B$917.0M
FY2023$6.3B$1.0B
FY2024$6.4B$864.0M
FY2025$6.2B$187.0M

Cash flows

FY2025: $700.0M from operations, $384.0M free after investment (dashed).

Organon & Co. operating and free cash flow by fiscal year
Organon & Co. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$858.0M$431.0M
FY2023$799.0M$538.0M
FY2024$939.0M$588.0M
FY2025$700.0M$384.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$6.2B-2.9%1Y
EBITDA
$1.3B-19.6%1Y
Net profit
$187.0M-78.4%1Y
Cash from operations
$700.0M-25.5%1Y
Free cash flow
$384.0M-34.7%1Y
Revenue CAGR, 3Y
0.2%
Net profit CAGR, 3Y
-41.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$6.2B$1.3B$187.0M$384.0M24.9%-2.9%-78.4%

Monthly returns

Month-by-month returns of OGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$12.9B
Liabilities$12.1B
Equity$752.0M
Paid-in capital$167.0M
Retained earnings$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; OGN highlighted.

P/E against peers

OGN trades at 18.8x earnings against a peer median of 24.2x (a 22% discount).

Not shown (no positive earnings and no EV / Sales): Arcus Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Organon & Co.OGNthis companyP/E ↓ discount$3.5B18.8x4.7x24.9%9.0x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
ICU Medical, Inc.ICUI$3.4B4607.1x1.6x0.0%14.7x
Concentra Group Holdings Parent, Inc.CON$3.2B19.2x8.1x42.3%12.7x
Integer Holdings CorporationITGR$3.1B30.6x1.8x5.9%15.2x
Arcus Biosciences, Inc.RCUS$3.1B-8.8x4.9x-55.9%-8.9x
Peer median—24.2x2.7x7.0%13.1x

Year-to-date ROI

OGN since 1 January, against earlier years.

Historical volatility

OGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Organon & Co. operating margin by fiscal year
Organon & Co. operating margin by fiscal year
DateOperating margin
FY202227.6%
FY202321.2%
FY202423.2%
FY202519.7%
LineFY2025
Cost of revenueCost Of Revenue$2.9B
Gross profitGross Profit$3.3B
Operating expensesOperating Expense$2.1B
Research and developmentResearch And Development$366.0M
Selling, general and administrativeSelling General And Administration$1.7B
Total expensesTotal Expenses$5.0B
Operating incomeOperating Income$1.2B
Pretax incomePretax Income$425.0M

Learn while you research

Academy chapters picked for Organon & Co. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 11.49 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →